HIV/AIDS

Enrollment initiated in phase I/II study for new HIV entry inhibitor

Published in Biotech Business Week, April 11th, 2005

AnorMED, Inc., (AOM) has initiated enrollment into a phase Ib/IIa trial to evaluate the potential of AMD070, an oral CXCR4 HIV entry inhibitor, in HIV-infected patients.

The company's clinical program for AMD070 is being conducted by leading investigators at the U.S. Adult AIDS Clinical Trials Group (ACTG), which is supported by the National Institute of Allergy and Infectious Diseases at the National Institute of Health.

"This clinical study in HIV patients will determine if AMD070 has the potential to become a new and important anti-HIV drug. AMD070, a member of a new class of HIV drugs called entry inhibitors, prevents the virus from infecting...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2005-04-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry